Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Update Il y a 4 ans
Reference: NCT01068483

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists of a dose escalation part followed by a MTD expansion part. Once the MTD has been defined, the MTD expansion part will be opened for enrollment.


Inclusion criteria

  • Breast Cancer,colon cancer,Ovarian Cancer,Endometrium Cancer

Links